ArticleJournal of cancer research and clinical oncology2015
ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens.
Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Predictive modeling of peripheral blood EGFR positivity in patients with advanced primary non-small cell lung cancer.Translational lung cancer research · 2026Article
- Concordance study of bronchial biopsy tissues and matched bronchial brushing cytology specimens in driver gene detection of non-small cell lung cancer.Frontiers in oncology · 2026Article
- A Novel Microfluidic Platform for Circulating Tumor Cell Identification in Non-Small-Cell Lung Cancer.Micromachines · 2025Article
- Detection of EGFR mutations in patients with suspected lung cancer using paired tissue-plasma testing: a prospective comparative study with plasma ddPCR assay.Scientific reports · 2024Article
- Combination of microwave ablation and systemic treatments achieve a long survival time for a patient with metachronous advanced double primary lung and colon adenocarcinoma: A case report.Oncology letters · 2024Article
- Ultra-rapid Idylla™Frontiers in oncology · 2023Article
- Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA.Therapeutic advances in medical oncology · 2023Review
- Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.Journal of cancer research and clinical oncology · 2022Article
- Advances in Microfluidics for the Implementation of Liquid Biopsy in Clinical Routine.Advances in experimental medicine and biology · 2022Article
- EGFR mutations subset in Chinese lung squamous cell carcinoma patients.Molecular medicine reports · 2018Article
- Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing.Yonsei medical journal · 2018Article
- High concordance of EGFR mutation status between sputum and corresponding tissue specimens of late-stage lung cancers using amplification refractory mutation system-PCR.International journal of clinical and experimental pathology · 2018Article
- Identification of EGFR mutations in cytological specimens of non-small cell lung carcinoma from a single institute.International journal of clinical and experimental pathology · 2018Article
- Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.The oncologist · 2017Article
- CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.Radiology · 2016Article
- Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer.OncoTargets and therapy · 2016Article
- Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey.Journal of pathology and translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEpidermal growth factor receptor (EGFR) mutation analysis is becoming a routine clinical practice for lung adenocarcinoma patients. Most patients with lung cancer are diagnosed at an advanced stage of the disease and are not suitable for surgical therapy. In many cases, cytologic specimens may be the only tissue available for diagnostic and molecular testing. Therefore, it is important to determine what condition the cytologic specimens should be in for adequately analyzing EGFR mutation status.
methodsFifty-eight paired cytologic and lung adenocarcinoma histologic specimens that satisfied 3 requisite parameters (>2 ng/μl DNA concentration, >30 tumor cells content, and >25% tumor percentage) were collected. Exons 18 through 21 of the EGFR gene were analyzed by amplification refractory mutations system.
resultsThe EGFR mutation concordance rate between cytologic specimens and corresponding histologic specimens was 100%. A set of 30 paired specimens from different sites (lung and pleural fluids) from the same patient exhibited 100% concordance in the EGFR mutation analysis results.
conclusionsIn this study, EGFR mutation presented a convenient and reliable method for the analysis of cytologic specimens that satisfied 3 requisite parameters (>2 ng/μl DNA concentration, >30 tumor cells content, and >25% tumor percentage). We concluded that the specimens from both primary lung adenocarcinomas and metastatic lesions (such as pleural fluids) can be used for EGFR mutation analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.